A cross-sectional study of bone turnover markers in healthy premenopausal women

被引:83
作者
de Papp, Anne E.
Bone, Henry G.
Caulfield, Michael P.
Kagan, Risa
Buinewicz, Anna
Chen, Erluo
Rosenberg, Elizabeth
Reitz, Richard E.
机构
[1] Merck & Co Inc, N Wales, PA 19454 USA
[2] Michigan Bone & Mineral Clin, Detroit, MI USA
[3] Quest Diagnost Nichols Inst, San Juan Capistrano, CA USA
[4] Fdn Osteoporosis Res & Educ, Oakland, CA USA
关键词
bone turnover marker; reference range; premenopausal; NTX; bone ALP; oral contraceptives;
D O I
10.1016/j.bone.2007.01.008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Biochemical markers of bone turnover (BTMs) provide useful information in the diagnosis and management of metabolic bone diseases. Currently, there exist few published reference ranges for bone markers in healthy premenopausal women using the newer, automated assays of bone turnover. This cross-sectional study of healthy premenopausal women was performed to determine reference ranges for four different markers of bone turnover and to compare reference ranges in users and non-users of oral contraceptives (OCs). Methods: Urinary N-telopeptide of type I collagen (NTX) was determined from fasting second morning-void urine of healthy premenopausal women. In addition, fasting serum was collected for determination of C-telopeptide of type I collagen (CTX), bone-specific alkaline phosphatase (bone ALP), and N-terminal propeptide of type I procollagen (PINP). Subjects underwent central dual energy X-ray absorptiometry and completed a questionnaire regarding medical history and activities known to affect bone health. Results: Serum and urine samples were collected from 237 healthy premenopausal women (119 OC users and 118 non-users) between the ages of 28 and 45 years. The mean age of subjects was 37 years, with a mean bone mineral density T-score of -0.1 at the lumbar spine and 0.0 at the total hip. Logarithmic transformation produced normal distributions for all markers but NTX. Mid-95% ranges for each marker were generally consistent with those reported by manufacturers. For each BTM examined, values were skewed toward the lower end of the range. Median NTX levels for OC users and non-users were 16.0 and 29.0 nmol/mmol creatinine, respectively. The mid-95% ranges for NTX in OC users and non-users were 3-60 and 4-64 nmol/mmol creatinine, respectively. Median levels of CTX, bone ALP, and PINP were also lower in OC users than non-users. The mean level of each BTM was significantly lower in OC users than non-users (P<0.01), whereas reference ranges (geometric mean +/- 2 SD) were somewhat similar for the two groups. Conclusion: Values obtained from this well-characterized population provide reference ranges for BTMs in healthy premenopausal women. Median and mean BTM levels for OC users were consistently lower compared with non-users; thus, separate reference ranges are required for these two groups of premenopausal women. The relevance of premenopausal reference ranges for postmenopausal women remains uncertain. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:1222 / 1230
页数:9
相关论文
共 42 条
[1]   Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: The OFELY Study [J].
Albrand, G ;
Munoz, F ;
Sornay-Rendu, E ;
DuBoeuf, F ;
Delmas, PD .
BONE, 2003, 32 (01) :78-85
[2]   Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The Fracture Intervention Trial [J].
Bauer, DC ;
Black, DM ;
Garnero, P ;
Hochberg, M ;
Ott, S ;
Orloff, J ;
Thompson, DE ;
Ewing, SK ;
Delmas, PD .
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (08) :1250-1258
[3]   Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis [J].
Bjarnason, NH ;
Sarkar, S ;
Duong, T ;
Mitlak, B ;
Delmas, PD ;
Christiansen, C .
OSTEOPOROSIS INTERNATIONAL, 2001, 12 (11) :922-930
[4]   Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial [J].
Black, Dennis M. ;
Schwartz, Ann V. ;
Ensrud, Kristine E. ;
Cauley, Jane A. ;
Levis, Silvina ;
Quandt, Sara A. ;
Satterfield, Suzanne ;
Wallace, Robert B. ;
Bauer, Douglas C. ;
Palermo, Lisa ;
Wehren, Lois E. ;
Lombardi, Antonio ;
Santora, Arthur C. ;
Cummings, Steven R. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (24) :2927-2938
[5]   Ten years' experience with alendronate for osteoporosis in postmenopausal women [J].
Bone, HG ;
Hosking, D ;
Devogelaer, J ;
Tucci, JR ;
Emkey, RD ;
Tonino, RP ;
Rodriguez-Portales, JA ;
Downs, RW ;
Gupta, J ;
Santora, AC ;
Liberman, UA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (12) :1189-1199
[6]   RISK-FACTORS FOR HIP FRACTURE IN WHITE WOMEN [J].
CUMMINGS, SR ;
NEVITT, MC ;
BROWNER, WS ;
STONE, K ;
FOX, KM ;
ENSRUD, KE ;
CAULEY, JC ;
BLACK, D ;
VOGT, TM .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (12) :767-773
[7]  
Delmas PD, 2000, OSTEOPOROSIS INT, V11, pS2, DOI 10.1007/s001980070002
[8]   ESTROGEN EFFECTS ON CALCITRIOL LEVELS IN POSTMENOPAUSAL WOMEN - A COMPARISON OF ORAL VERSUS TRANSDERMAL ADMINISTRATION [J].
DICK, IM ;
PRINCE, RL ;
KELLY, JJ ;
HO, KKY .
CLINICAL ENDOCRINOLOGY, 1995, 43 (02) :219-224
[9]   Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate [J].
Eastell, R ;
Barton, I ;
Hannon, RA ;
Chines, A ;
Garnero, P ;
Delmas, PD .
JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 (06) :1051-1056
[10]   Ethnic variation in bone density in premenopausal and early perimenopausal women: Effects of anthropometric and lifestyle factors [J].
Finkelstein, JS ;
Lee, MLT ;
Sowers, M ;
Ettinger, B ;
Neer, RM ;
Kelsey, JL ;
Cauley, JA ;
Huang, MH ;
Greendale, GA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (07) :3057-3067